AMEND news in Tag: MEN1
-
Somatotrophinoma and primary hyperparathyroidism: a novel MEN1-like syndrome?
Researchers have reported what may be the first known case of a change (variant) in the CHEK2 gene causing a combination of conditions that closely resemble Multiple Endocrine Neoplasia type 1 (MEN1).
Click here to learn more
-
Whole genome and exome sequencing of pNENs to investigate PRRT response
A new study looked at the DNA of pancreatic neuroendocrine tumours (pNETs) to see whether genetic changes could explain why some patients respond better than peptide receptor radionuclide therapy (PRRT) than others.
Click here to learn more
-
2026 London Marathon Record!
This year, the London Marathon is held on Sunday 26th April, with a record number of runners participating in aid of AMEND! In addition to our Charity Ballot place recipient, Ed, three other runners are getting their running shoes on to raise essential funds for AMEND. We wish them all the luck in the world and hope that you can sponsor one or more of them.
CLICK HERE FOR MORE INFORMATION
-
National Cancer Plan for England Launched
Wednesday 4th February 2026, marked as World Cancer Day, saw the publication of the detailed National Cancer Plan for England by the Department of Health & Social Care
Click here to learn more
-
New MEN1 App Launched
Today, AMEND has launched an app for MEN1 members ensuring that information is always at hand, even if offline. The app replaces the traditional, expensive, and slow-to-receive hardcopy MEN1 Member Pack.
Click here for more information
-
2026 Peer Support Meetings
We are pleased to confirm the dates for our 2026 Peer Support Meetings for those with MEN or PPGL syndromes. You can book now to connect with others.
Click here to view dates and to book
-
New Phase 3 Clinical Trial for Hyperinsulinism Drug
The upLIFT study, phase 3 clinical trial of ersodetug for tumour hyperinsulinism (HI), a drug from Rezolute (a late-stage rare disease company) is now enrolling participants through 2 UK centres.
Click to learn more
-
2025 Information Day Speakers Confirmed!
Our line-up of excellent expert speakers are now confirmed for our 2025 Annual Patient Information Day in central London. Our friendly and essential information event for patients and partners affected by multiple endocrine neoplasia, inherited paraganglioma syndromes, and adrenocortical cancer is free and includes lunch and refreshments. Come along and find out why it's so highly rated!
Click here for more information and to book
-
New Webcast! Parathyroid Surgery
Our latest Webcast on the topic of Parathyroid Surgery launches on Saturday 29th March at 08:00. In this episode, AMEND CEO, Jo Grey, talks to Mr Shad Khan, Endocrine Surgery at Oxford University Hospitals, about parathyroid surgery, particularly in the context of MEN1.
Click here to watch this and other Webcasts
-
2025 Peer Support Meetings Confirmed
We are delighted to report that our Peer Support Volunteers have now scheduled a number of meetings (online or in-person) where you can meet others either to give or receive peer support. Grab a coffee and join us!
Click here for more information